VIVEbiotech´s exhibited at BioEurope 2017 event, the most relevant event in the Biotechnology field in Europe that took place in Berlin from the 5th to the 8th of November.

More than two thousand biotech Companies were present at BioEurope, among them, very well-known Companies involved in the Gene Therapy field.

VIVEbiotech´s team exhibited at  European Society Gene and Cell Therapy (ESGCT) event that was hold in Berlin from the 16th to the 20th of October 2017.

Juan Carlos Ramirez (CSO/CTO) and Natalia Elizalde (Business Development Director) attended this congress.

Two collaborative profiles have been published today in Enterprise European Network (EEN).

The Enterprise European Network  helps businesses innovate and grow on an international scale. It is the world’s largest support network for small and medium-sized enterprises (SMEs) with international ambitions. 

Different Biotechnology Companies have actively participated in extended report from the Diario Vasco daily newspaper. Among these Companies, VIVEbiotech´s CEO, put a reasoned viewpoint  considering that there are some Companies, as VIVEbiotech, that have been seeding during years allowing that Guipuzcoa is already a relevant area in the biotechnology sector.

VIVEbiotech has become a partner of Alliance for Regenerative Medicine 

Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide.

This year, VIVEbiotech´s team will also participate in the 23^rd edition of Europe's largest partnering conference. 

Juan Carlos Ramirez, Chief Technology/Scientific Officer and Natalia Elizalde, Business Development Director, will be present at this event that will be hold in Berlin.

Please, do not hesitate to contact us to organize a meeting there so we will find a specific slot from the 6^th to the 8^th of November.

VIVEbiotech´s main interests are:

• Meeting with Companies developing its own Gene Therapy pipeline that are looking for a flexible Company able to adapt to its requirements in terms of Lentiviral vector development and manufacture.
• Meeting with Companies with interest in Lentisoma´s vector Technology (Non-integrative episomal lentiviral vector) to discuss about collaborative options.
• Building a strong network allowing us to continue positioning as key players in viral vector manufacture field.